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BACKGROUND: KRAS codons 12 and 13 mutations predict resistance to anti-EGFR monoclonal antibodies (moAbs) in metastatic
colorectal cancer. Also, BRAF V600E mutation has been associated with resistance. Additional KRAS mutations are described in CRC.
METHODS: We investigated the role of KRAS codons 61 and 146 and BRAF V600E mutations in predicting resistance to cetuximab plus
irinotecan in a cohort of KRAS codons 12 and 13 wild-type patients.
RESULTS: Among 87 KRAS codons 12 and 13 wild-type patients, KRAS codons 61 and 146 were mutated in 7 and 1 case, respectively.
None of mutated patients responded vs 22 of 68 wild type (P¼0.096). Eleven patients were not evaluable. KRAS mutations were
associated with shorter progression-free survival (PFS, HR: 0.46, P¼0.028). None of 13 BRAF-mutated patients responded vs 24 of
74 BRAF wild type (P¼0.016). BRAF mutation was associated with a trend towards shorter PFS (HR: 0.59, P¼0.073). In the
subgroup of BRAF wild-type patients, KRAS codons 61/146 mutations determined a lower response rate (0 vs 37%, P¼0.047) and
worse PFS (HR: 0.45, P¼0.023). Patients bearing KRAS or BRAF mutations had poorer response rate (0 vs 37%, P¼0.0005) and PFS
(HR: 0.51, P¼0.006) compared with KRAS and BRAF wild-type patients.
CONCLUSION: Assessing KRAS codons 61/146 and BRAF V600E mutations might help optimising the selection of the candidate patients
to receive anti-EGFR moAbs.
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RAS and RAF proteins play a key role in the control of cellular
growth, proliferation and differentiation (Bos, 1989; Wickenden
et al, 2008) KRAS-activating mutations reduce or abolish intrinsic
GTPase activity of the protein, leading to its constitutive activation
(Conlin et al, 2005) Similarly BRAF V600E mutation induces
structural changes in RAF protein which increase its kinase activity
(Wan et al, 2004) Activated RAS and RAF are responsible for the
disregulation of RAS/RAF/MAPKs signalling pathway.
KRAS codons 12 and 13 activating mutations are widely
recognised as predictors of resistance to the treatment with anti-
EGFR monoclonal antibodies (moAbs) in metastatic colorectal
cancer (mCRC) patients (Karapetis et al, 2008; Amado et al, 2008).
Based on retrospectively collected data and post hoc analyses of
large phase III studies, the European Medicines Agency has
restricted the use of cetuximab to the treatment of patients with
KRAS codons 12 and 13 wild-type disease (about the 60% of the
overall population; EMEA, 2008) and the American Society of
Clinical Oncology has similarly recommended in a recent
provisional clinic opinion not to administer anti-EGFR moAbs to
patients with KRAS codons 12 or 13 mutated tumours (Allegra
et al, 2009). Nevertheless, in a systematic review and meta-analysis,
Linardou et al reported a very high specificity (0.93, (0.83–0.97))
and a much lower sensitivity (0.47, (0.43–0.52)) of KRAS analysis
in predicting resistance to anti-EGFR moAbs in mCRC, thus
underlining the need for additional predictive markers to be
combined with KRAS codons 12 and 13 evaluation, for a more
accurate patients’ selection (Linardou et al, 2008).
A recently published experience found a correlation between
BRAF V600E-activating mutation, mutually exclusive with KRAS
ones, and resistance to the treatment with cetuximab and
panitumumab administered alone or in combination with
chemotherapy (Di Nicolantonio et al, 2008).
On the basis of the above-mentioned evidences, around 50% of
candidate patients would be excluded from receiving anti-EGFR
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effectiveness. However, as cetuximab or panitumumab mono-
therapies determine a response rate of about 10% regardless of the
line of treatment and no more than 23% of patients respond to the
combination of cetuximab and irinotecan (Cunningham et al,
2004; Van Cutsem et al, 2007; Jonker et al, 2007) it is plausible that
the selection of candidate patients to receive an anti-EGFR moAb
might be further slightly refined.
Additional KRAS-activating mutations, involving codons 61 and
146 (Edkins et al, 2006) occur with frequencies ranging from 1 to
4% in CRCs. These relatively rare mutations, as well as codons 12
and 13 mutations, are responsible for the oncogenic constitutive
activation (Buhrman et al, 2007; Feig and Cooper, 1988) of RAS/
RAF/MAPKs pathway and they might account for up to a 10% of
resistant patients bearing KRAS codons 12 and 13 and BRAF wild-
type tumours.
To optimise the selection of patients who are more likely to
benefit from anti-EGFR we investigated in a cohort of patients
treated with the combination of cetuximab and irinotecan and
bearing KRAS codons 12 and 13 wild-type tumours, the association
of KRAS codons 61 and 146 mutations and BRAF V600E mutation
with clinical outcomes.
MATERIALS AND METHODS
Patients
Patients with irinotecan-refractory mCRC (ie, progressed during
or within 3 months after treatment with an irinotecan-based
regimen) were considered eligible for our study if they had an
histologically confirmed diagnosis of EGFR-positive adenocarci-
noma, measurable and evaluable disease according to RECIST
criteria (Therasse et al, 2000) available paraffin-embedded samples
of primary lesions and had undergone a salvage cetuximab-
irinotecan treatment.
All patients’ samples were screened for KRAS codons 12 and 13
mutations, constituting the group named ‘overall population’ and
only those with wild-type disease were included in the group
named ‘study population’ and further analysed for KRAS codons
61, 146 and BRAF V600E mutations.
Response was evaluated every 8 weeks by CT-scan. According to
RECIST criteria, patients were categorised as responders if they
achieved complete response (CR) or partial response (PR), or non-
responders if they showed stable (SD) or progressive disease (PD).
Progression-free survival (PFS) was defined as the time from the
beginning of chemotherapy to first appearance of progression or
death by any cause. Overall Survival (OS) was defined as the time
from the beginning of therapy to death or last follow-up (censored
observations).
Patients’ characteristics and their outcomes were unknown to
investigators performing genetic analyses. The study was approved
by local Ethical Committees and patients provided signed
informed consent to mutational analyses.
Mutational analyses
Mutational analyses were centralised and performed at the
Laboratory of Molecular Biology, Institute of Biochemistry,
University of Urbino.
DNA was extracted from tissue samples using the Qiamp DNA
FFPE tissue Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s protocol.
Hotspot mutation sites were amplified by polymerase chain
reaction (PCR). Primer sequences and cycling conditions are
shown in Table 1. Primers design was performed by mean of PSQ
Assay Design Software (Biotage, Uppsala, Sweden).
Each PCR reaction contained 50–150ng of DNA, 0.4mM of each
primer, 12.5ml of PCR Master Mix (Diatheva, Fano, Italy) and
0.625U of HotStarTaq polymerase (Diatheva) in a total volume of
25ml. Successful and specific amplification of the region of
interest was verified by visualising 5ml of the PCR product on a
2% agarose gel.
Preparation of the single-stranded DNA template for pyrose-
quencing analysis was performed using the PSQ Vacuum Prep
Tool (Biotage) according to the manufacturer’s instructions.
A portion of 20ml of biotinylated PCR product was immobilised
on streptavidin-coated Sepharose High-Performance beads (Amer-
sham Biosciences, Piscataway, NJ, USA) and processed to obtain a
single-stranded DNA using the PSQ 96 Sample Preparation Kit
(Biotage) according to the manufacturer’s instructions.
The template was incubated with 0.4mmoll
 1 sequencing primer
at 801C for 2min in a PSQ96 plate. The sequencing by synthesis
reaction of the complementary strand was automatically per-
formed on a PSQ 96MA instrument (Biotage) using PyroGold
reagents (Biotage).
Statistical analysis
Results of KRAS and BRAF mutational analyses were used as
categorical variables (presence or absence of the mutation). The
primary end-point was the correlation between KRAS codon 61,
146, BRAF V600E mutations and response to treatment in the
study population. Two-tailed Fisher’s exact test was used to
compare proportions of responders and non-responders according
to their mutational status. The PFS and OS analyses were
determined according to the Kaplan–Meier method and survival
curves were compared using the log-rank test. Statistical
significance was set at Po0.05 for a bilateral test.
Table 1 Primers and polimerase chain reaction (PCR) conditions for mutational analyses
Mutations Primers PCR conditions
KRAS codon 12–13 F: 50-GGCCTGCTGAAAATGACTGAA
R: 50-[Btn]-TTCGTCCACAAAATGATTCTGA
Seq: 50-TATAAACTTGTGGTAGTTGG
100 at 951C, 40 cycles of 1500 at 951C, 3000 at 641C, 4000 at
721C and 50 at 721C
KRAS codon 61 F: 50-CAGACTGTGTTCTCCCTTCTCA
R: 50-[Btn]CTCATGTACTGGTCCCTCATTG
Seq: 50-ATATTCTCGACACAGCAG
100 at 951C, 40 cycles of 1500 at 951C, 3000 at 661C, 3000 at
721C and 50 at 721C
KRAS codon 146 F: 50-TGGACAGGTTTTGAAAGATATTTG
R: 50-[Btn]-ATTAAGAAGCAATGCCCTCTCAAG
Seq: 50-AATTCCTTTTATTGAAACAT
100 at 951C, 40 cycles of 1500 at 951C, 3000 at 641C, 3000 at
721C and 50 at 721C
BRAF codon 600 F: 50-ATGCTTGCTCTGATAGGAA
R: 50-[Btn]-GCATCTCAGGGCCAAA
Seq:50-GGTGATTTTGGTCTAGCTAC
100 at 951C, 40 cycles of 1500 at 951C, 3000 at 541C, 4000 at
721C and 50 at 721C
Abbrevations: Btn¼biotynilated; Seq¼sequencing primer.
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A total of 138 patients with mCRC, who had received cetuximab
and irinotecan in four Italian Medical Oncology Units, have been
screened for KRAS codons 12 and 13 mutations.
Clinical and pathological characteristics of the overall popula-
tion and of the study population are summarised in Table 2.
Eighty-seven (63%, 52 men and 35 women) of 138 patients had KRAS
codons 12 and 13 wild-type disease and entered the study popula-
tion. Median age was 66 (range: 41–79). Of these 87, 44 (51%), 39 (44%)
a n d4( 5 % )p a t i e n t sh a da nE C O GP So f0 ,1a n d2 ,r e s p e c t i v e l y .
All patients received cetuximab plus irinotecan according to
the schedule commonly used in clinical practice: cetuximab
250mg/sqm i.v., day 1 weekly (loading dose: 400mg/sqm i.v.,
day 1 in the first cycle) or 500mg/sqm i.v., day 1 every 2 weeks and
irinotecan 180mg/mq i.v., day 1 every 2 weeks.
In the study population, according to RECIST criteria, 1 CR and
23 PRs were reported, for an overall response rate (RR) of 28%. Of
the patients, 35 (40%) achieved SD and 28 (32%) experienced PD.
At the time of the analysis, 81 (93%) patients underwent disease
progression and 63 (72%) died. Median PFS and median OS were
4.1 and 9.7 months, respectively.
Mutational status of KRAS codons 61 and 146
The mutational analyses of codons 61 and 146 were successfully
performed in 76 out of 87 cases. KRAS was mutated in codon 61 or
146 in 7 (8%) and 1 (1%) cases, respectively. None of the 8 patients
bearing KRAS 61 or 146 mutated disease responded to the
treatment, whereas 22 (32%) of 68 patients with wild-type disease
achieved response (P¼0.096; Table 3B). KRAS 61 and 146
mutations were associated with significantly shorter PFS (median
Table 3 Study flow chart and correlations with response to treatment: (A) KRAS codons 12 and 13 analysis in the overall population; (B) KRAS 61 and 146
mutations and (B) BRAF V600E mutation in study population (KRAS codons 12 and 13 subgroup)
KRAS  12 and 13 mutations in the overall population
N=138
KRAS  12/13 mut
N=51
KRAS  12/13 wt
N=87
Non responders 48 (94%) 63 (72%)
Responders 3 (6%) 24 (28%)
Fisher’s exact
test: P=0.004 
STUDY POPULATION (N=87)
KRAS 61 and 146 mutations BRAF V600E mutation 
N=76 (11 not evaluable) N=87
KRAS  61/146 mut
N=8
KRAS  61/146 wt
N=68
BRAF mut
N=13
BRAF wt
N=74
Non responders 8 (100%) 46 (68%) 13 (100%) 50 (68%)
Responders 0 (0%) 22 (32%) 0 (0%)
Fisher ‘s exact test: P=0.096 Fisher ’s exact test: P=0.016
24 (32%)
Table 2 Patients’ characteristics
Overall population
(N¼138)
Study population
(N¼87)
n (%) n (%)
Age
Median (range) 61 (42–77) 66 (41–79)
Sex
Male 76 (55) 52 (60)
Female 62 (45) 35 (40)
ECOG PS
0 70 (51) 44 (51)
1 61 (44) 39 (44)
2 7 (5) 4 (5)
Number of metastatic
sites
1 33 (24) 21 (24)
2 63 (46) 41 (47)
X2 42 (30) 25 (29)
Sites of metastases
Liver 110 (80) 63 (72)
Lung 72 (52) 45 (52)
Lymph nodes 35 (25) 24 (27)
Peritoneum/pelvis 31 (22) 20 (23)
Other 46 (33) 29 (33)
Skin toxicity
G0—G1 84 (61) 44 (51)
XG2 54 (39) 43 (49)
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(0.11–0.88), P¼0.028; Figure 1A), whereas no significant differ-
ences were detected in OS (median OS: 9.7 vs 14.7 months in KRAS
61 and 146 wild-type; HR: 0.69 (0.24–1.75), P¼0.390; Figure 1B).
Mutational status of BRAF codon 600
Among the 87 patients of the study population, BRAF was mutated
in 13 cases (15%). KRAS codons 61, 146 and BRAF V600E
mutations were mutually exclusive. None of the patients bearing
BRAF mutation responded to the treatment, in comparison with
24(32%) of 74 patients with BRAF wild-type disease (P¼0.016;
Table 3C). BRAF mutation was associated with a trend towards
shorter PFS (median PFS: 2.6 vs 4.4 months in BRAF wild-type;
HR: 0.59 (0.24–1.07), P¼0.073; Figure 1C) and with significantly
shorter OS (median OS: 4.1 vs 13.9 months in BRAF wild-type; HR
0.51 (0.18–0.95), P¼0.037; Figure 1D).
Combined analysis of KRAS codons 61 and 146 and BRAF
codon 600 mutational status
Among 74 patients with BRAF wild-type disease, KRAS codons 61
and 146 mutational status was successfully assessed in 68 cases.
Eight (11%) tumours were KRAS 61 or 146 mutated. None of
patients with KRAS 61 or 146 mutated tumours responded, in
comparison with 22 (37%) of 60 KRAS 61 and 146 wild-type
patients (P¼0.047; Table 4A). Also in BRAF wild-type subpopula-
tion, KRAS codons 61 and 146 mutations were associated with
shorter PFS (median PFS: 3.8 vs 5.3 months in KRAS 61 and 146
wild-type; HR: 0.45 (0.10–0.85), P¼0.023; Figure 2A), whereas no
significant differences were reported in terms of OS (median OS:
9.7 vs 14.8 months in KRAS 61 and 146 wild-type; HR: 0.32
(0.21–1.66), P¼0.320; Figure 2B).
In the subgroup of 68 patients with KRAS 61 and 146 wild-type
tumours, BRAF was mutated in 8 cases. None of BRAF-mutated
patients obtained a response, whereas 22 (37%) out of 60 patients
with BRAF wild-type disease responded (P¼0.047; Table 4B).
BRAF mutation was associated with a trend towards shorter PFS
(median PFS: 3.9 vs 5.3 months in BRAF wild-type; HR: 0.69 (0.26–
1.52), P¼0.306; Figure 3A) and OS (median OS: 9.0 vs 14.8 months
in BRAF wild-type; HR: 0.63 (0.20–1.60), P¼0.279; Figure 3B).
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Figure 1 (A) Progression-free survival and (B) overall survival curves according to KRAS codons 61 and 146 mutational status in study population.
(C) Progression-free survival and (D) overall survival curves according to BRAF codon 600 mutational status in study population.
Table 4 (A) KRAS 61 and 146 mutations in BRAF wild-type subgroup
and (B) BRAF V600E mutation in KRAS 61 and 146 wild-type subgroup:
correlation with response
N =74 (6 not evaluable) 68 evaluable
KRAS  61/146 mut
N=8
KRAS 61/146 wt
N=60
Non responders 8 (100%) 38 (63%)
Responders 0 (0%) 22 (37%)
Fisher’s exact test: P=0.047
N =68
BRAF  mut
N=8
 BRAF wt
N=60
Non responders 8 (100%) 38 (63%)
Responders 0 (0%) 22 (37%)
Fisher’s exact test: P=0.047
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with tumours presenting whatever mutation responded to the
treatment, in comparison with 22 (37%) of 60 patients with KRAS
61 and 146 and BRAF wild-type disease (P¼0.0005; Table 5).
Wild-type patients reported significantly longer PFS (median PFS:
5.3 vs 3.3 months; HR: 0.51 (0.22–0.77), P¼0.006; Figure 4A) and
OS (median OS: 14.8 vs 9.7 months; HR: 0.54 (0.24–0.92),
P¼0.027; Figure 4B).
DISCUSSION
The molecular test for KRAS mutations has been introduced in the
routine clinical practice of the oncologists facing mCRC (Allegra
et al, 2009). Since the first report of KRAS predictive value for
resistance to cetuximab (Lie `vre et al, 2006), investigators looked
at most of the frequent mutations (ie, those affecting codons
12 and 13). Therefore, also the most reliable demonstrations of
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Figure 2 (A) Progression-free survival and (B) overall survival curves
according to KRAS codons 61 and 146 mutational status in BRAF wild-type
subgroup.
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Figure 3 (A) Progression-free survival and (B) overall survival curves
according to BRAF codon 600 mutational status in KRAS codon 61 and 146
wild-type subgroup.
Table 5 Combined analysis of KRAS 61/146 and BRAF V600E mutation
in study population: correlation with response
N =87 (6 not evaluable) 81 evaluable
KRAS 61/146 or
BRAF mut
N=21 
KRAS  61/146 and BRAF
wt
N=60
Non responders 21 (100%) 38 (63%)
Responders 0 (0%) 22 (37%)
Fisher’s exact test: P=0.0005
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Figure 4 (A) Progression–free survival and (B) overall survival curves of
patients with KRAS codon 61 or 146 or BRAF-mutated disease compared
to those of patients with wild-type disease.
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that is, those deriving from post hoc analyses of randomised studies
(Karapetis et al, 2008; Amado et al, 2008; Van Cutsem et al, 2009),
investigated only codons 12 and 13 genetic variants. Even if quite
specific for non-responsiveness, KRAS codon 12 and 13 analysis
suffers from low sensitivity. In fact around 35% of wild-type patients
experience rapid disease progression.
This background led to the search for alternative predictive
factors, such as EGFR ligands expression (Khambata-Ford et al,
2007) or polymorphisms (Garm Spindler et al, 2009), alterations in
other EGFR signalling pathways (ie, PTEN/PI3K/AKT; Loupakis
et al, 2009) or in downstream effectors of KRAS (ie, BRAF). In
particular, Di Nicolantonio et al (2008) recently found that none of
11 BRAF-mutated patients, among 79 KRAS codon 12 and 13 wild
type, responded to anti-EGFR moAbs. BRAF mutation also
predicted for an unfavourable outcome in terms of both PFS and
OS. From a methodological standpoint mutational analyses are
quite more appealing with respect to other techniques such as
immunohistochemistry or gene expression profiling. In fact, the
determination of mutational status is easily reproducible, qualita-
tive, less expensive and does not require fresh tumour tissue
sampling. Taking into account these considerations and the
growing knowledge on minor oncogenic KRAS mutations in
codons 61 and 146 (mutually exclusive with those in codons 12 and
13), we conducted this retrospective study to verify whether the
combined analyses of such rare KRAS mutations and BRAF codon
600 variants are related to resistance to cetuximab plus irinotecan.
In the present analysis, 13, 7 and 1 patient among 87 patients with
KRAS codon 12 and 13 wild-type disease had tumour bearing
BRAF V600E, KRAS codon 61 and KRAS codon 146 mutation,
respectively. None of the KRAS codon 12 or 13 wild-type patients
bearing an alteration on KRAS codon 61, 146 or BRAF codon 600
responded to treatment. Moreover patients with mutated tumours
had a significantly worse outcome both in terms of PFS and OS.
Such data indicate that, even if much more rare than codon 12 or
13 mutations, codon 61 and 146 as well as BRAF mutations also
seem to predict resistance to cetuximab. As these rare KRAS
mutations and BRAF mutations are mutually exclusive with the
others, it seems reasonable to test for their presence only in
patients with KRAS codon 12 and 13 wild-type tumours.
Considering our data, it seems that among those subjects that
are expected not to have codon 12 or 13 mutations (around 60% of
mCRC patients), testing for BRAF and rare KRAS mutations would
exclude around 25% of patients, with obvious saving of economic
resources and sparing unnecessary toxicities.
The quest for the most sensible and specific tools for selecting
patients who are more likely to benefit from anti-EGFR inhibitors
is an issue acquiring a great relevance for two main reasons. On
one hand, in addition to the present indication for the use of anti-
EGFR moAbs, the results from a recent phase III randomised trial
(Van Cutsem et al, 2009) led to the approval of cetuximab for
KRAS codon 12 and 13 wild-type patients also in the first-line
setting. On the other hand, it has been proven that in such setting
the choice of using an anti-EGFR moAb precludes the possibility of
coadministering the antiangiogenic antibody bevacizumab, even in
KRAS codon 12 and 13 wild-type patients (Tol et al, 2009; Hecht
et al, 2009). Moreover, it should be noted that the choice of the
best upfront treatment for each patient is not only to offer the best
palliation, but it may even influence the possibility for cure (Adam
et al, 2009). In this regard it should be considered that there are
different ongoing randomised studies evaluating the impact of
moAbs in the adjuvant setting, where the clinical impact of reliable
predictors of outcome will be even greater.
In conclusion, our results suggest that KRAS testing power for
predicting resistance to anti-EGFR might be improved by
including codon 61 and 146 mutational analysis. This finding
may have rapid and important implications for routine clinical
practice. Moreover, this study confirms the recent finding that
indicates BRAF V600E mutation as a promising additional marker
for resistance. Such preliminary and retrospective results should
be verified on samples from patients enrolled in randomised
studies of anti-EGFR moAbs vs best supportive care.
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